​

Medifast, Inc.

NYSE:MED Stock Report

Market Cap: US$140.3m

Medifast (MED) Stock Overview

Through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. More details

MED fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings are forecast to decline by an average of 39.6% per year for the next 3 years


MED Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

MED logo
Medifast
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 1 Analyst

Digital Tools And OPTAVIA ASCEND Will Modernize Coaching Experience

Key Takeaways Streamlining coach development and upgrading digital tools are expected to enhance customer acquisition, retention, and personalized solutions, potentially boosting revenue and margins. Product diversification and increased coach recruitment amid economic slowdowns are seen as key strategies for supporting future revenue growth.
View narrative
US$14.44
FV
6.9% undervalued intrinsic discount
-23.67%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
1 day ago author updated this narrative
View Medifast Community

Medifast, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Medifast
Historical stock prices
Current Share PriceUS$13.44
52 Week HighUS$22.66
52 Week LowUS$11.57
Beta0.89
1 Month Change-0.37%
3 Month Change12.75%
1 Year Change-28.43%
3 Year Change-92.36%
5 Year Change-91.93%
Change since IPO144.36%

Recent News & Updates

Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price

Jul 03
Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price

Medifast: Coach Surge Fuels Growth

Jul 03

Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target

May 01
Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target

Recent updates

Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price

Jul 03
Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price

Medifast: Coach Surge Fuels Growth

Jul 03

Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target

May 01
Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target

Medifast: Strong Balance Sheet, But I Lack Conviction In The Turnaround

Jan 20

An Intrinsic Calculation For Medifast, Inc. (NYSE:MED) Suggests It's 41% Undervalued

Jan 09
An Intrinsic Calculation For Medifast, Inc. (NYSE:MED) Suggests It's 41% Undervalued

Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry

Dec 11
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
author-image

GLP-1 Medication Surge And Stalling Coach Productivity Threaten Revenue Decline

The adoption of weight loss medications impacts Medifast's business model, threatening future revenue and customer acquisition.

Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued

Nov 06

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

Sep 03

Medifast Business Continues To Shrink, Stock Still Risky

Aug 27

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Jun 26

Medifast: Significant Undervaluation Even As Struggles Persist

May 24

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

Medifast: Cheap Valuation, Uncertain Future

Mar 20

Medifast Is Getting Attractive

Mar 07

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26
Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05
Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19
At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Shareholder Returns

MEDUS Personal ProductsUS Market
7D-8.4%-1.1%0.5%
1Y-28.4%-6.5%14.1%

Return vs Industry: MED underperformed the US Personal Products industry which returned -8.4% over the past year.

Return vs Market: MED underperformed the US Market which returned 12.4% over the past year.

Price Volatility

Is MED's price volatile compared to industry and market?
MED volatility
MED Average Weekly Movement6.4%
Personal Products Industry Average Movement7.4%
Market Average Movement6.4%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: MED has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MED's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980504Dan Chardmedifastinc.com

Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. It also provides bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups, as well as provides coaching support along with community, nutrition, and healthy habits, and helps people in their weight loss journey.

Medifast, Inc. Fundamentals Summary

How do Medifast's earnings and revenue compare to its market cap?
MED fundamental statistics
Market capUS$140.34m
Earnings (TTM)-US$7.00m
Revenue (TTM)US$543.45m
0.3x
P/S Ratio
-19.9x
P/E Ratio

Is MED overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MED income statement (TTM)
RevenueUS$543.45m
Cost of RevenueUS$141.88m
Gross ProfitUS$401.58m
Other ExpensesUS$408.57m
Earnings-US$7.00m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.68
Gross Margin73.89%
Net Profit Margin-1.29%
Debt/Equity Ratio0%

How did MED perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/17 04:46
End of Day Share Price 2025/07/17 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medifast, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anand VankawalaAvondale Partners
Kara AndersonB. Riley Securities, Inc.
Scott Van WinkleCanaccord Genuity